@article{9cfe43943e9342c2ba548bfdb872999e,
title = "Reply to: “Correction for length bias reduces the mortality benefit from hepatocellular carcinoma surveillance”",
author = "Singal, {Amit G.} and Jorge Marrero and Parikh, {Neehar D.}",
note = "Funding Information: Dr. Singal{\textquoteright}s research is supported by National Cancer Institute (NCI) R01 CA212008, U01 CA271887, and CA222900. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NCI. The funding agencies had no role in design and conduct of the study; collection, management, analysis, and interpretation of the data; or preparation of the manuscript. Funding Information: Amit G. Singal has served on advisory boards and/or consultant for Bayer, Eisai, Genentech, Exelixis, Bristol Meyers Squibb, Astra-Zeneca, Wako Diagnostics, Glycotest, Exact Sciences, Roche, and TARGET Pharmasolutions. He has received research funding from Gilead. Jorge Marrero has served as a consultant for Glycotest. Neehar Parikh has served as a consultant or on advisory boards for Bayer, Wako Diagnostics, Exact Sciences, Glycotest, and Freenome. ",
year = "2023",
month = aug,
doi = "10.1016/j.jhep.2023.05.008",
language = "English (US)",
volume = "79",
pages = "e90--e92",
journal = "Journal of Hepatology",
issn = "0168-8278",
publisher = "Elsevier",
number = "2",
}